As we reported last August, the FDA has already approved Erelzi^®, Sandoz’s biosimilar version of Amgen’s psoriasis drug Enbrel.^® However, the head of generics at Novartis (Sandoz’s parent) told Reuters this week that their biosimilar product will likely not go on sale before 2018 because of ongoing patent protection issues.

Stay tuned for further updates on Big Molecule Watch.